Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Rhea-AI Summary
Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 2026 Jefferies Healthcare Conference on June 3, 2026, at 4:55 p.m. ET. A webcast will be available on the company’s investor relations website for 30 days.
Amphastar develops and sells injectable, inhalation, intranasal, and API products.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AMPH
On the day this news was published, AMPH gained 1.54%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AMPH gained 2.17% while close peers showed mixed moves: HROW +3.35%, BGM +10.25%, TLRY +0.09%, EVO -0.34%, AVDL 0%. With no peers in the momentum scanner and no same-day peer headlines, the move appears company-specific rather than a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Negative | -20.9% | Flat revenue but sharply lower profit and compressed gross margins. |
| May 06 | Conference presentation | Neutral | +2.2% | Announcement of Bank of America Health Care Conference presentation. |
| Apr 30 | Earnings date notice | Neutral | +1.5% | Scheduled Q1 2026 release and conference call timing details. |
| Apr 06 | Conference presentation | Neutral | +0.6% | Needham Healthcare Conference appearance with multiple executives presenting. |
| Feb 26 | FY 2025 earnings | Positive | -23.6% | Strong Q4 and full-year 2025 revenues and earnings metrics reported. |
Earnings reports with weaker profitability have coincided with sharp selloffs, while conference and scheduling updates have typically seen modest positive reactions.
Over the last six months, Amphastar has combined earnings volatility with steady investor outreach. Q4 2025 results on Feb 26 showed strong revenues but were followed by a -23.63% move. Q1 2026 earnings on May 7 highlighted margin pressure and saw shares fall -20.93%. In contrast, conference and event notices on Apr 6, Apr 30, and May 6 produced small gains between 0.64% and 2.18%. Today’s Jefferies conference announcement fits that non-fundamental, modestly positive pattern.
Market Pulse Summary
This announcement highlights Amphastar’s continued participation in major healthcare conferences, providing management with a platform to discuss strategy and pipeline developments. Recent history shows sharp stock reactions around earnings, with moves of -20.93% and -23.63% after profit pressure, while conference notices have coincided with small gains. Investors typically monitor future earnings quality, margin trends, and pipeline execution alongside these outreach events to assess how well messaging aligns with financial performance.
Key Terms
forward-looking statements regulatory
securities and exchange commission regulatory
form 10-k regulatory
form 10-q regulatory
fda filings regulatory
clinical trials medical
AI-generated analysis. Not financial advice.
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
About Amphastar Pharmaceuticals, Inc.
Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredients, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.
Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 7, 2026, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire